醫療外骨骼的全球市場：市場規模和佔有率分析（依組件、類型和肢體）-工業需求預測（截至 2030 年）

2023年，全球醫療外骨骼市場規模將達4.858億美元，2030年將達63.368億美元，複合年增長率為44.8%。

該行業的成長主要得益於殘疾人數量的快速增加、老年人口的增加以及骨科手術數量的增加。

北美引領世界市場

北美將在 2023 年成為最大的市場，佔據 55% 的佔有率，並在未來幾年取得巨大進步。 這是由於老年人口快速成長、政府對外骨骼的支持力度加大、神經系統疾病發生率上升。

由於醫療保健資金增加、最近的產品批准以及需要行動和康復支持的患者數量不斷增加，亞太地區正在以最快的速度取得進展。

依細分市場分析

依組件劃分，硬體類別將於 2023 年以 60% 的佔有率引領行業，並在未來幾年以 45.0% 的複合年增長率增長。 這是因為外骨骼是使用不同的硬體製造的，例如電力系統、感測器、控制系統和執行器。

依類型劃分，由於最近的改進，功率類型佔有很大佔有率。

在四肢方面，下肢外骨骼在2023年佔據領先地位。 這可能是由於下半身區域疾病的盛行率增加，包括腳踝、腳、膝蓋和臀部。

本報告分析了全球醫療外骨骼市場，包括市場的基本結構和最新情況、主要促進和抑制因素以及全球、依地區和主要國家的市場規模前景（金額（基數、 2017-2030），依組件、類型和肢體劃分的詳細趨勢、當前市場競爭狀況以及主要公司概況。

目錄

第一章研究範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場指標

第五章產業展望

• 市場動態
  • 趨勢
  • 促進因素
  • 抑制因素/課題
  • 促進/抑制因子影響分析
• 新型冠狀病毒感染 (COVID-19) 的影響
• 波特五力分析

第六章世界市場

• 摘要
• 市場收入：依組成部分劃分（2017-2030 年）
• 市場收入：依類型劃分（2017-2030 年）
• 市場收入：依肢體分類（2017-2030 年）
• 市場收入：依地區劃分（2017-2030 年）

第七章北美市場

• 摘要
• 市場收入：依組成部分劃分（2017-2030 年）
• 市場收入：依類型劃分（2017-2030 年）
• 市場收入：依肢體分類（2017-2030 年）
• 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第 11 章中東與非洲 (MEA) 市場

第12章美國市場

• 摘要
• 市場收入：依組成部分劃分（2017-2030 年）
• 市場收入：依類型劃分（2017-2030 年）
• 市場收入：依肢體分類（2017-2030 年）

第十三章加拿大市場

第14章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

• 市場參與者及其提供的產品/服務的列表
• 主要公司的競爭基準
• 各大公司的產品基準
• 近期策略發展狀況

第30章公司簡介

• Ekso Bionics Holdings Inc.
• ReWalk Robotics Ltd.
• Parker-Hannifin Corporation
• BIONIK Laboratories Corp.
• Rex Bionics Ltd.
• B-Temia Inc.
• Bioventus LLC
• Hocoma AG

第31章附錄

The medical exoskeleton market generated a value of USD 485.8 million in 2023, which will increase to USD 6,336.8 million, with a 44.8% CAGR, by 2030.

The growth of this industry is mainly because of the surging count of people with physical disabilities, the increasing elderly population, and the rising number of orthopedic surgeries.

For instance, as per the World Health Organization, an estimated 1.3 billion individuals, or 1 out of 6 people globally, experience significant disability.

Moreover, as per the United Nations, the number of people who are 65 years and above is rising at a faster rate compared to those below this age. Also, the percentage of the worldwide population aged 65 and above is likely to reach 16% in 2050 from 10% in 2022.

Furthermore, more than 300 million orthopedic operations are performed across the globe every year, 75% of which take place in developed nations.

In addition, the surging number of road accidents, strokes, and severe injuries, is also aiding the expansion of this industry. The WHO says that around 1.3 million people die annually because of road traffic crashes. Therefore, the rising acceptance of medical exoskeletons for the curing of injuries is boosting industry expansion.

North America Leading the Global Market

North America was the largest contributor to the industry in 2023, with a 55% share, and it will advance significantly in the coming years. This is because of the surging elderly population, rising government support for exoskeletons, and high incidence of neurological ailments.

For example, Human in Motion Robotics Inc. (HMR), in September 2022, declared a CAD 663,000 contract from Innovative Solutions Canada for the Department of National Defence Canada.

The contract is for the Canadian government to buy HMR's next-generation lower-extremity exoskeleton, XoMotion, which is intended to remove people's reliance on wheelchairs and enable them total mobility.

APAC is advancing at the fastest rate, owing to the increasing funding in healthcare, recent product approvals, and a growing patient pool requiring mobility and rehabilitation support.

Segmentation Analysis

The hardware category, based on component, led the industry in 2023, with a 60% share, and it will propel at a 45.0% CAGR in the coming years. This can be because exoskeletons are produced using different pieces of hardware, such as powered systems, sensors, control systems, and actuators.

The powered category, based on type, was the larger contributor to the industry, owing to the recent improvements in them. For example, Stanford University, with investment from the NIH, has developed an exoskeleton that rapidly adapts to users' movement while they walk normally.

Additionally, major players in this industry are concentrating on incorporating cutting-edge technologies like AI, to improve their product performance. AI increases the human potential, along with the efficiency of the devices.

In 2023, lower-extremity exoskeletons led the extremity category. This can be credited to the increasing prevalence of lower body parts disability, including the ankles, feet, and knee & hip joints.

Competitive Landscape

Businesses are concentrating on partnerships & acquisitions:

In November 2021, Ottobock declared the acquisition of 100% shares of suitX, a U.S.-based business spun out of the Robotics & Human Engineering Lab at the University of California, which is mostly involved in medical exoskeletons R&D.

In April 2022, Blackrock Neurotech declared that it will partner for R&D with Phantom Neuro for its patent-pending Phantom X system.

With the rising number of people with physical disabilities across the globe, the medical exoskeleton industry will continue to grow in the coming years.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by component
  • 1.4.2. Market size breakdown, by type
  • 1.4.3. Market size breakdown, by extremity
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Component (2017-2030)
• 6.3. Market Revenue, by Type (2017-2030)
• 6.4. Market Revenue, by Extremity (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Component (2017-2030)
• 7.3. Market Revenue, by Type (2017-2030)
• 7.4. Market Revenue, by Extremity (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Component (2017-2030)
• 8.3. Market Revenue, by Type (2017-2030)
• 8.4. Market Revenue, by Extremity (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Component (2017-2030)
• 9.3. Market Revenue, by Type (2017-2030)
• 9.4. Market Revenue, by Extremity (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Component (2017-2030)
• 10.3. Market Revenue, by Type (2017-2030)
• 10.4. Market Revenue, by Extremity (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Component (2017-2030)
• 11.3. Market Revenue, by Type (2017-2030)
• 11.4. Market Revenue, by Extremity (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Component (2017-2030)
• 12.3. Market Revenue, by Type (2017-2030)
• 12.4. Market Revenue, by Extremity (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Component (2017-2030)
• 13.3. Market Revenue, by Type (2017-2030)
• 13.4. Market Revenue, by Extremity (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Component (2017-2030)
• 14.3. Market Revenue, by Type (2017-2030)
• 14.4. Market Revenue, by Extremity (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Component (2017-2030)
• 15.3. Market Revenue, by Type (2017-2030)
• 15.4. Market Revenue, by Extremity (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Component (2017-2030)
• 16.3. Market Revenue, by Type (2017-2030)
• 16.4. Market Revenue, by Extremity (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Component (2017-2030)
• 17.3. Market Revenue, by Type (2017-2030)
• 17.4. Market Revenue, by Extremity (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Component (2017-2030)
• 18.3. Market Revenue, by Type (2017-2030)
• 18.4. Market Revenue, by Extremity (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Component (2017-2030)
• 19.3. Market Revenue, by Type (2017-2030)
• 19.4. Market Revenue, by Extremity (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Component (2017-2030)
• 20.3. Market Revenue, by Type (2017-2030)
• 20.4. Market Revenue, by Extremity (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Component (2017-2030)
• 21.3. Market Revenue, by Type (2017-2030)
• 21.4. Market Revenue, by Extremity (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Component (2017-2030)
• 22.3. Market Revenue, by Type (2017-2030)
• 22.4. Market Revenue, by Extremity (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Component (2017-2030)
• 23.3. Market Revenue, by Type (2017-2030)
• 23.4. Market Revenue, by Extremity (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Component (2017-2030)
• 24.3. Market Revenue, by Type (2017-2030)
• 24.4. Market Revenue, by Extremity (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Component (2017-2030)
• 25.3. Market Revenue, by Type (2017-2030)
• 25.4. Market Revenue, by Extremity (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Component (2017-2030)
• 26.3. Market Revenue, by Type (2017-2030)
• 26.4. Market Revenue, by Extremity (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Component (2017-2030)
• 27.3. Market Revenue, by Type (2017-2030)
• 27.4. Market Revenue, by Extremity (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Component (2017-2030)
• 28.3. Market Revenue, by Type (2017-2030)
• 28.4. Market Revenue, by Extremity (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Ekso Bionics Holdings Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. ReWalk Robotics Ltd.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Parker-Hannifin Corporation
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. BIONIK Laboratories Corp.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Rex Bionics Ltd.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. B-Temia Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Bioventus LLC
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Hocoma AG
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports